Find disease awareness content and relevant supporting materials
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Current protocols use G-CSF to mobilize hematopoietic progenitor cells from matched sibling and volunteer unrelated donors. Unfortunately, this process requires...
Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation.
Although peripheral blood stem cells (PBSC) have worldwide become the predominant source of progenitor cells for hematopoietic stem cell transplantation (HSCT), debate about their role compared with bone marrow (BM)...
Gamida Cell presents efficacy and safety results of phase III study of omidubicel for hematologic malignancies at the 2021 TCT meetings of ASTCT and CIBMTR.
Gamida Cell announced the results of a Phase III clinical study of omidubicel presented in an oral session at the Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood & Marrow Transplant Research (CIBMTR), or the TCT Meetings.
Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report
The London patient (participant 36 in the IciStem cohort) underwent allogeneic stem-cell transplantation with cells that did not express CCR5 (CCR5Δ32/Δ32); remission was reported at 18 months after analytical treatment interruption (ATI).
Change of indication for G Lasta for the mobilization of hematopoietic stem cells into peripheral blood in allogeneic blood stem cell transplantation in Japan.- Kyowa Kirin.
Kyowa Kirin Co., Ltd. announced that the company received an approval for partial change of approved indication of G-Lasta [KRN125, generic name: pegfilgrastim (genetical recombination) , long-acting Granulocyte Colony-Stimulating Factor (G-CSF) preparation] according to the additional indication, dosage, and administration for the mobilization of hematopoietic stem cells into peripheral blood in allogeneic blood stem cell transplantation in Japan.